Revenue ($m) 12.y6, up 24pc from year-earlier 10.2
Pretax loss ($m) 3.5 v 2.4
Net loss ($m) 3.5 v 2.4
No interim dividend
The development of new products in the pipeline for skin regeneration biotechnology company PolyNovo has been pushed back at least six months thanks to COVID-19, according to CEO Paul Brennan.
The delay to new products comes as the business also experienced a slowdown in second-quarter sales, which constrained its revenue growth to 24 per cent for the first half, as it hit $12.6 million.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
